Login / Signup

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.

Lyndon Marc EvansPlamen KozlovskiPäivi M PaldániusJames E FoleyVaishali BhosekarCarmen SerbanAngelo Avogaro
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2017)
Novartis.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes
  • patient reported